Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Achillion Pharmaceuticals, a developer of small molecule drugs, has appointed Joseph Truitt as its new vice president of business development and chief commercial officer.
Subscribe to our email newsletter
Mr Truitt, who joins Achillion from ViroPharma, which recently acquired Lev Pharmaceuticals, will be responsible for identifying, evaluating and executing corporate partnerships, strategic initiatives and new product opportunities.
Most recently, beginning in October 2007, Mr Truitt was vice president of business development and product strategy for Lev Pharmaceuticals. Mr Truitt holds a BS degree in marketing from LaSalle University, Philadelphia, and an MBA degree from St Joseph’s University, Philadelphia.
Michael Kishbauch, president and CEO of Achillion, said: “I am pleased to welcome Joe to Achillion at this important time in the company’s growth. Joe’s broad commercial experience and his proven track record in deal-making will be great assets to Achillion in the coming year.”